Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CD19-mafodotin, Anti-CD19-mcMMAF, Anti-CD19-vcMMAE + [3] |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H65N5O8 |
InChIKeyMFRNYXJJRJQHNW-DEMKXPNLSA-N |
CAS Registry745017-94-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11232 | Denintuzumab mafodotin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 2 | PR | 01 Aug 2016 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | US | 01 Oct 2015 | |
Recurrent Grade 3b Follicular Lymphoma | Phase 2 | US | 01 Oct 2015 | |
B-cell lymphoma refractory | Phase 1 | US | 01 Feb 2013 | |
Burkitt Lymphoma | Phase 1 | US | 01 Feb 2013 | |
Mantle-Cell Lymphoma | Phase 1 | US | 01 Feb 2013 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | US | 01 Feb 2013 | |
Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | US | 01 Feb 2013 |
Phase 2 | 81 | gqfkuvovez(nuddnkkool) = elsxqndwki ijbphzjrqr (vvqvlxfwmz, getnihhdoh - bmywnsxzjg) View more | - | 17 May 2019 | |||
gqfkuvovez(nuddnkkool) = zgqvwtnzam ijbphzjrqr (vvqvlxfwmz, glnzjufynj - vfneivixar) View more | |||||||
Phase 1 | 22 | roiowiuxje(ebyjimpcvb) = poutdilgyo igezlrqaar (kosgysllsp ) View more | - | 20 May 2014 |